Clinical Trials Logo

Ischemic Stroke clinical trials

View clinical trials related to Ischemic Stroke.

Filter by:

NCT ID: NCT03554642 Recruiting - Ischemic Stroke Clinical Trials

Walkbot Robotic Training for Improvement in Gait

Start date: September 2016
Phase: Phase 3
Study type: Interventional

This clinical study will involve up to 30 ischemic stroke inpatients during their stay at Burke Rehabilitation Hospital. Participants will be randomized to receive 30 additional minutes of therapy every day, for a total of 2 weeks (14 days). One group will receive 30 minutes of standard physical therapy focused on pre-gait or gait training activities, while the experimental group will receive 30 minutes of Walkbot with Augmented Reality. Both groups will receive the same time in therapy aimed at gait training.

NCT ID: NCT03551093 Recruiting - Ischemic Stroke Clinical Trials

THE IMPACT- 24M TRIAL (IMPlant Augmenting Cerebral Blood Flow in Mild Strokes Trial 24 Hours From Stroke Onset)

ImpACT- 24M
Start date: May 14, 2018
Phase: Phase 3
Study type: Interventional

Study Population: Subjects with Mild Acute Ischemic Stroke in the anterior circulation within 24 hours from onset. Study objectives: 1. Identify the personal stimulation level for each patient based on physiological biomarkers 2. Identify improvement in stroke symptoms during ISS treatment at the personal stimulation level

NCT ID: NCT03545607 Not yet recruiting - Ischemic Stroke Clinical Trials

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study

MASTERS-2
Start date: June 2018
Phase: Phase 3
Study type: Interventional

A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.

NCT ID: NCT03543319 Recruiting - Ischemic Stroke Clinical Trials

Norwegian Microemboli in Acute Stroke Study

NOR-MASS
Start date: June 2018
Phase:
Study type: Observational

BACKGROUND: The cause of ischemic stroke remains undetermined in 30-40% of the cases, but circulating blood clots (thromboemboli) are a postulated common denominator in approx. 75% of patients. Transcranial Doppler monitoring (TCDM) is a non-invasive method of detecting circulating microemboli (CME) in the human cerebral circulation. The method is not used systematically in unselected groups of patients with repeated long-term registrations. New ultrasound equipment is ambulatory, less unpleasant for the patient and allows extended monitoring sessions. This may vastly simplify the implementation of TCDM as a clinically useful diagnostic tool. AIMS: Determine the usefulness of TCDM in acute stroke diagnostics by assessing prevalence and frequency of CME in unselected patients with ischemic stroke, the influence of antithrombotic drugs on CME and the relationship between MES and recurrent stroke or transient ischemic attack (TIA). HYPOTHESES: Prevalence and frequency of CME are higher during the first 24 hours than at later follow-up. Stroke etiology can be assessed by the presence or absence of CME. Presence of CME is associated with increased risk of recurrent TIA of stroke within 3 months and 1 year. Cessation of CME after the start of antithrombotic treatment is associated with reduced risk of recurrent TIA or stroke.

NCT ID: NCT03496545 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Efficacy of Bromocriptine on Febrile Adults With Acute Neurologic Diseases

Start date: July 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.

NCT ID: NCT03496064 Enrolling by invitation - Ischemic Stroke Clinical Trials

Registry for Evaluating Outcome of Acute Ischemic Stroke Patients Treated With Mechanical Thrombectomy.

BEYOND-SWIFT
Start date: November 1, 2017
Phase:
Study type: Observational

The Bernese-European RegistrY for ischemic stroke patients treated Outside current guidelines with Neurothrombectomy Devices using the SOLITAIREā„¢ FR With the Intention For Thrombectomy (BEYOND-SWIFT) is a retrospective, multi-center, non-randomized observational study aims to investigate the safety and efficacy of a Medtronic market-released neurothrombectomy device (applied as initial devices used for intervention) in acute ischemic stroke patients who do not fulfill treatment eligibility according to current guidelines. Patients will be treated or were treated at the discretion of the investigator, independent of participation in this registry. Primary Analysis is the Impact of successful reperfusion on functional outcome at day 90 in patients presenting with large infarct cores (ASPECTS<6) or minor symptoms (NIHSS<8).

NCT ID: NCT03494920 Recruiting - Ischemic Stroke Clinical Trials

DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval

Start date: April 27, 2018
Phase: Phase 3
Study type: Interventional

The study will be a multicentre, prospective, randomized, open label, blinded endpoint (PROBE) phase 3 trial (2 arm with 1:1 randomization) in ischemic stroke patients within 4.5 hours of stroke onset. Randomised patients will be stratified for site of baseline arterial occlusion into one of three groups: 1. internal carotid artery (ICA) 2. middle cerebral artery (MCA) 3. basilar artery (BA). Patients will be randomised to either bridging intravenous thrombolysis with endovascular clot retrieval (ECR), or direct endovascular clot retrieval.

NCT ID: NCT03494530 Not yet recruiting - Ischemic Stroke Clinical Trials

Lixiana Acute Stroke Evaluation Registry

LASER
Start date: June 1, 2018
Phase:
Study type: Observational

Edoxaban (also referred to as Lixiana) is an anti-clotting drug, approved by Health Canada for the prevention of stroke in patients with atrial fibrillation (abnormal heart rhythm). This study is being done to try to determine the best time to start apixaban treatment after an ischemic stroke has occurred. The purpose of the LASER study is to determine the safety of early edoxaban use after TIA/ischemic stroke in patients with atrial fibrillation using advanced MR imaging. This study will also gather information about participant general well being, mental status, and the effects of the TIA/stroke on daily living, as well as CT and MRI of the brain.

NCT ID: NCT03485820 Recruiting - Ischemic Stroke Clinical Trials

A Novel Transition Program to Reduce Disability After Stroke

COMPASS
Start date: January 18, 2018
Phase: N/A
Study type: Interventional

This study evaluates a program designed to help individuals transition home from inpatient rehabilitation following an ischemic or hemorrhagic stroke. Half of the participants will receive a stroke education program while the other half will receive an environmental modifications program.

NCT ID: NCT03481777 Recruiting - Ischemic Stroke Clinical Trials

Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)

RESIST
Start date: April 3, 2018
Phase: N/A
Study type: Interventional

Our primary aim is to investigate whether remote ischemic conditioning (RIC) as an adjunctive treatment reduce neurological impairment at 24 hours and improve long-term recovery in acute stroke patients as an adjunct to standard treatment.